Ask about this productRelated genes to: IL32 antibody
- Gene:
- IL32 NIH gene
- Name:
- interleukin 32
- Previous symbol:
- -
- Synonyms:
- NK4, TAIF, TAIFb, TAIFd
- Chromosome:
- 16p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 2005-02-08
- Date modifiied:
- 2014-11-18
Related products to: IL32 antibody
Related articles to: IL32 antibody
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic condition impacting over 30% population, yet the dynamic changes in macrophage composition from steatosis to steatohepatitis (metabolic dysfunction-associated steatohepatitis, MASH) remain unclear. Here, by integrating single-nucleus transcriptomics, spatial multi-omics and proteomics on human samples, we delineate the evolving landscape of hepatic macrophages across the MASLD spectrum. Our analysis reveals a progressive depletion of Kupffer cells accompanied by the emergence of diverse, phenotypically distinct macrophage subsets. Spatial multi-omics further demonstrates that disease progression toward MASH is marked by an accumulation of antigen-presenting, phagocytic GPNMB macrophages, supported by IL32-producing hepatocytes. These macrophages showed an adaptive metabolic and pro-inflammatory phenotype that is tightly regulated by both spatial context and disease stage. Identified macrophage markers enable patient stratification by disease activity and its stage across independent clinical cohorts. Our study sheds light on the diversity of macrophage identities and metabolic-adaptive phenotypes during the progression of MASLD. - Source: PubMed
Publication date: 2026/05/18
Boesch MarkusAnak SerayEl Abyad DaniaOstyn TessaAntoranz AsierMy Van TrieuNewhouse DanielMyers CaitlynVan Melkebeke LukasPalmer JeremySaffarzadeh NajmehChui Jonathan Sai-HongFeio-Azevedo RitaSmets LenaShankar GautamDubroja Lakić NikolinaCalvo Paula LongásVoet ThierryClark JamesCockell SimonLannoo MatthiasDeleus EllenJaekers JorisTopal HalitTopal BakiSchneider Kai MarkusVacca MicheleAllison MichaelEkstedt MattiasBoursier JeromeBugianesi ElisabettaRatziu VladDe Smet FrederikBoeckx BramDaly Ann KSchattenberg Jörn MVerbeek JefBosisio FrancescaLambrechts DietherRoskams TaniaSchneider Carolin VFrancque SvenKorf HannelieHärtlova AnettaTiniakos DinaAnstee Quentin Mvan der Merwe SchalkGovaere Olivier - Gastric cancer (GC) is heterogeneous, and current mismatch repair (MMR)-based classifications incompletely predict response to immune checkpoint inhibitors (ICIs). - Source: PubMed
Shen KeZhang YanqiangWang ZhiqinXu RuixingHe JintaoZhou MengyaLu YimingZhu DanniWei YizhouZhu WeiweiYang QingXu ZhiyuanHu CanPan SiweiCheng Xiangdong - Behçet disease (BD) is multisystem inflammatory vasculitis affecting vessels of all types and sizes. Vascular involvement represents one of the most severe and life-threatening manifestations, associated with increased morbidity and mortality. The aim of this study was to investigate the role of cytokines and nitric oxide (NO) in the pathogenesis of BD, which could potentially highlight a new biomarker, capable of discriminating between patients with and without vascular involvement. - Source: PubMed
Publication date: 2026/05/16
Ghozali NourelhoudaHadjimi ZohraAbdesselam ZahiraBouzid FerielIhammichene SarahKediha Mohamed IslamTerahi MalikaBelkacem Habiba Amroun AitHakem DjanetteMoulay SakinaLaraba NazimTouil-Boukoffa ChafiaBelguendouz Houda - Cardiovascular diseases remain a leading cause of death worldwide, driven by complex pathological mechanisms involving various cytokines and inflammatory responses. IL-32, a recently discovered cytokine, has emerged as a key player in the pathogenesis of cardiovascular diseases, including atherosclerosis, myocardial infarction, and heart failure. This review summarizes the biological characteristics of IL-32 and its role in cardiovascular diseases, explores its involvement in inflammatory responses and other pathological processes, and evaluates its potential as both a biomarker and a therapeutic target. Collectively, this review aims to provide new insights for the prevention and treatment of cardiovascular diseases. - Source: PubMed
Publication date: 2026/04/22
Qiu LingyueYe JingLiu LingJi Qingwei - Elevated remnant lipoproteins are a causal risk factor for atherosclerotic cardiovascular disease. We tested the hypothesis that low-grade inflammation can explain part of the increased risk of peripheral artery disease (PAD) and myocardial infarction conferred by elevated remnant lipoproteins; we also explored the causal effect of genetically elevated remnant cholesterol on inflammatory cytokine levels. - Source: PubMed
Publication date: 2026/05/01
Wadström Benjamin NWulff Anders BPedersen Kasper MNordestgaard Børge G